Reversible, Orally Bioavailable Small-Molecule Inhibitors Occupy the Substrate Tunnel of the Thioesterase Domain of Fatty Acid Synthase
Preprint
Abstract
Fatty acid synthase (FASN) is the sole enzyme capable of lipogenesis in cells and is upregulated in many cancers. Herein we report the discovery and development of SBP-5917 ( 78S ), a novel, reversible, small-molecule probe which targets the thioesterase (TE) domain of FASN. SBP-5917 and other compounds in the series possess IC 50 < 1 µM and < 5 µM for inhibiting recombinantly purified FASN-TE and cellular FASN respectively. Co-crystal structures of our inhibitors bound to the FASN-TE domain show that they are positioned in the substrate tunnel of the enzyme. Biochemical and biophysical analyses quantify the strength of compound binding and demonstrate their selectivity for FASN-TE. Preliminary pharmacokinetic studies indicate promising in vivo potency for many of the compounds in the series. SBP-5917 is the first structurally validated, reversible inhibitor of FASN-TE with demonstrated cellular target engagement and can serve as a chemical probe to investigate FASN as a therapeutic target. ABSTRACT FIGURE:Keywords
Funding Information
- National Cancer Institute (R01CA188694)
- National Cancer Institute (P30CA030199)
This publication has 72 references indexed in Scilit:
- Heterogeneity of HSCs in a Mouse Model of NASHHepatology, 2021
- Omeprazole, an inhibitor of proton pump, suppresses De novo lipogenesis in gastric epithelial cellsBiomedicine & Pharmacotherapy, 2020
- Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: Molecular mechanisms and therapeutic perspectivesBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2010
- Dietary stearate reduces human breast cancer metastasis burden in athymic nude miceClinical & Experimental Metastasis, 2009
- Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma modelInternational Journal of Cancer, 2008
- Structure and function of animal fatty acid synthaseLipids, 2004
- Biomarkers of dietary fatty acid intake and the risk of breast cancer: A meta‐analysisInternational Journal of Cancer, 2004
- Expression of the lipogenic enzyme fatty acid synthase (FAS) as a predictor of poor outcome in nephroblastoma: An interinstitutional studyMedical and Pediatric Oncology, 2003
- Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patientsCancer, 1996
- Review of Limited Systemic Absorption of Orlistat, a Lipase Inhibitor, in Healthy Human VolunteersThe Journal of Clinical Pharmacology, 1995